Mitchell S. Bloom

Mitchell S. Bloom

Partner Chair, Life Sciences Practice
Mitchell S. Bloom

Mitchell Bloom is national Chair of Goodwin’s Life Sciences Practice. Mr. Bloom specializes in representing public and private life science companies, as well as venture capital firms and investment banks focused on the life sciences sector, including matters involving biotechnology, medical devices, diagnostics and healthcare information technology.

Chambers USA: America’s Leading Lawyers for Business, The Legal 500 and LMG Life Sciences have all recognized Mr. Bloom as a national industry leader for his corporate finance and life sciences expertise.

Professional Activities

Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.

Professional Experience

Prior to joining Goodwin, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.

Recognition

Mr. Bloom is recognized nationally for his leadership in the life sciences industry and has been included in numerous legal guides for his corporate finance and life sciences expertise, including Chambers USA: America’s Leading Lawyers for Business, U.S. News-Best Lawyers and The Legal 500 United States. In addition, for the past two years he has been selected as a “Life Science Star” by LMG Life Sciences.  Most recently, Mr. Bloom was recognized as the #1 most active U.S. attorney for issuer side IPOs in 2015.

Under his leadership, Goodwin’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for three years running (2013-2015) and perennial nationwide recognition by Chambers USA.

Experience

Mr. Bloom's practice is focused on the representation of emerging and public life science companies and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic collaborations and commercial transactions.

His recent client representations include work with:

  • BeiGene in its $158 million initial public offering
  • CRISPR Therapeutics AG in its joint venture with Bayer valued up to $335 million, its $38 million additional Series B financing and publicly filed initial public offering
  • Proteostasis Therapeutics in its $50 million initial public offering and $65 million follow-on public offering
  • Quartet Medicine in its $595 million strategic collaboration with Merck
  • Ocata Therapeutics in its $379 million sale to Astellas Pharma Inc.
  • Global Blood Therapeutics in its $120 million initial public offering and $120 million follow-on public offering
  • Galapagos NV in its $275 million initial public offering and strategic collaboration with Gilead Sciences, valued up to $2 billion
  • Neos Therapeutics in its $75 million initial public offering
  • Celyad SA in its $100 million initial public offering
  • MyoKardia in its $46 million Series B financing and $54 million initial public offering
  • Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead Sciences valued up to $1.2 billion, collaborations with Monsanto and Shire Plc and its $43 million Series B financing
  • Voyager Therapeutics in its strategic collaboration with Genzyme for $100 million upfront and up to $745 million in milestone payments, and in its $45 million Series A financing, $60 million Series B financing and $70 million initial public offering
  • SAGE Therapeutics in its $90 million initial public offering and subsequent $138 million, $150 million and $175 million follow-on public offerings
  • Esperion in its $70 million initial public offering and subsequent $97 million and $201 million follow-on public offerings
  • Alnylam Pharmaceuticals in its $450 million follow-on public offering and in its strategic alliance and $700 million equity financing with Genzyme
  • TCR2 Therapeutics in its $44.5 million Series A financing
  • Magenta Therapeutics in its Series A Preferred Stock financing
  • Aptinyx in its $65 million Series A financing
  • Jounce Therapeutics in its $47 million Series A and $56 million Series B financings
  • Zafgen in its $96 million initial public offering and subsequent $137 million follow-on public offering
  • Inotek Pharmaceuticals in its $60 million initial public offering, $68.9 million follow-on public offering and $50 million follow-on public offering
  • DBV Technologies SA in its $92 million initial public offering
  • ProQR Therapeutics B.V. in its $97.5 million initial public offering
  • Warp Drive Bio in its innovative strategic partnership with Sanofi
  • Mevion Medical Systems in connection with its $55 million equity and debt financing and proposed initial public offering $200 million Series F financing
  • Relay Therapeutics in its $57 million Series A financing
  • Neon Therapeutics in its $55 million of Series A financing
  • Representation of underwriters in connection with public offerings for Reata Pharmaceuticals, Edge Therapeutics, Intrexon Corporation, Roka Biosciences, Tokai Pharmaceuticals, Flexion Therapeutics, NPS Pharmaceuticals, and Regulus Therapeutics

Credentials

Education

J.D., 1989
Boston College Law School
B.S., 1986
Suffolk University

(cum laude)

Admissions

Bar

Massachusetts
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers